DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gastric Adenocarcinoma

Intervention: Gleevec, Taxotere (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
John Kauh, MD, Principal Investigator, Affiliation: Emory University Winship Cancer Institute

Summary

The purpose of this trial is to test the combination of Gleevec® (also known as imatinib mesylate) and Taxotere (also known as docetaxel) in patients with incurable stomach cancer. This study is being performed to see if the combination of Gleevec and Taxotere is an effective treatment for incurable stomach cancer with minimal side effects.

Clinical Details

Official title: Phase II Trial of Gleevec (Imatinib Mesylate) and Taxotere (Docetaxel) as a Combined Regimen for Advanced Gastric Adenocarcinoma

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Determine if combination of Gleevec and Taxotere is effective treatment for incurable stomach cancer.

Secondary outcome: Determine toxicity of combination of Gleevec and Taxotere.

Detailed description: The purpose of this trial is to test the combination of Gleevec® (also known as imatinib mesylate) and Taxotere (also known as docetaxel) in patients with incurable stomach cancer. Gleevec is a pill form of chemotherapy and is indicated for the treatment of adult patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It is considered experimental for the treatment of stomach cancer. Taxotere (docetaxel) is a chemotherapy which is injected into the vein. It is approved for breast and lung cancer but has been shown to shrink many different types of tumors. Taxotere has been shown to shrink

stomach cancer in about 20% - 30% of patients treated with Taxotere only. This study is

being performed to see if the combination of Gleevec and Taxotere is an effective treatment for incurable stomach cancer with minimal side effects. Treatment on this study consists of two drugs, GleevecĀ® and Taxotere. Patients will be take four tablets of GleevecĀ® daily throughout the study. After one week of GleevecĀ®, patients will then begin receiving doses of Taxotere intravenously once a week for two weeks in a row followed by one week without Taxotere.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- This study is for patients with histologically confirmed unresectable gastric

adenocarcinoma and who have not received any chemotherapy other than 5-FU for adjuvant therapy either alone or in conjunction with radiation. Exclusion Criteria:

- Patients may not have received any chemotherapy agents other than 5-FU.

- Patients may not have received 5-FU for for therapy for metastatic gastric cancer.

- Patients must be more than 5 years free of another primary malignancy except: if

other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.

- Patients must not have Grade III/IV cardiac problems, or any severe and/or

uncontrolled medical disease (i. e. uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).

- Patient must not have had previously received radiotherapy to >/= 25% of the bone

marrow, or have had major surgery within 2 weeks prior to study entry

- Final eligibility for a clinical trial is determined by the health professionals

conducting the trial.

Locations and Contacts

Emory University Winship Cancer Institute, Atlanta, Georgia 30322, United States
Additional Information

Starting date: September 2004
Last updated: December 27, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017